1. Novel Basal Insulin Formulations in the Modern Era of T2D Management

3. PK/PD Assessment of Insulin Analogs

4. Intrasubject Variability With NPH Insulin (As Measured by GIR)

5. Basal Insulins Are Not Equivalent

6. Insulin PD Affected by BMI

7. PD of Degludec U100 at Steady State*

8. PD of Glargine U100 With Different Doses

9. PD of Regular Human Insulin U500 and U100*

10. PD of Degludec U100 and U200*

11. PD of Glargine U100 vs U300*

12. What Does All This Mean?

13. Insulin Glargine U300

14. EDITION 2: Glargine U300 vs U100*

15. EDITION Pooled Analysis

16. Insulin Degludec

17. Degludec vs Glargine U100: Insulin-Naive Patients* at 1 Y

18. Degludec vs Glargine U100*: Basal-Bolus With Prandial Insulin Aspart

19. Degludec Variable Dosing† vs Glargine U100 or Degludec Dosed Regularly*

20. New Insulin Pens

21. New Data at ADA 2016

22. Discussion: Use of Basal Insulin Analogs in T2D

23. Discussion: Considerations for Selecting or Switching Basal Insulin Analogs

24. Discussion: Other Considerations

25. Concluding Remarks

26. Abbreviations